Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combo Product Firms Want Simpler Adverse Event Reporting Structure

This article was originally published in The Gray Sheet

Executive Summary

FDA's proposed adverse event reporting requirements for combination products should be rewritten to simplify the way events are reported when multiple manufacturers are involved, firms say

You may also be interested in...

FDA’s Spring Regulatory Agenda Includes 17 Rx Drug-Related Rules

FDA’s prescription drug regulations in the works include rules on generic drug labeling, compounding, bioequivalence reports and safety reporting for combination products.

Drug Shortage Rules Surface In Latest FDA Regulatory Agenda

FDA has yet to prognosticate on a schedule for other FDASIA-mandated regulations; HHS says that FDA’s priorities for the coming year will involve devices and food, as well as promoting international regulatory cooperation.

Combination Products Office Finalizing Manufacturing, Adverse Event Rules

FDA says final rules on good manufacturing practices and adverse event reporting for combination products could be out as early as this fall.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts